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INTRODUCTION
Blinatumomab is the first-in-class bispecific T-cell engager antibody approved for the treatment of refractory acute lymphoblastic leukemia (ALL). 1, 2 It simultaneously binds endogenous CD3 1 cytotoxic T cells and CD19 1 B cells, resulting in T-celle mediated serial lysis of normal and malignant B cells. Although studies have been conducted into the incidence and severity of adverse events, cutaneous vasculitis has not been reported thus far.
CASE REPORT
A 14-year-old Chinese boy with Li Fraumeni syndrome and ALL underwent chemotherapy (Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 Study [MASPORE 2010] protocol) with re-induction twice with 6-mercaptopurine, methotrexate, and bortezomib. When he did not achieve remission, the decision was made to start him on intravenous blinatumomab (5 g/m 2 /d for days 1 through 7 inclusive, increased to 15 g/m 2 /d from day 8 onward). On day 15 of his treatment regimen, tender lesions developed on both feet associated with swelling.
Physical examination found 2 erythematous nodules on the dorsum of his right foot and a similar lesion on the dorsum of his left foot (Fig 1) . The lesions were tender on palpation, slightly warm, and blanchable. There were no other mucocutaneous lesions noted. He was otherwise well, and systemic examination was unremarkable. Results of laboratory testing, including full blood count, renal function, liver enzymes, and urinalysis, were within normal ranges. The initial differential diagnoses were disseminated fungal infections and immune/hypersensitivity reactions such as vasculitis. Histopathologic examination found vasculitic changes of the medium-sized blood vessels. The inflammatory infiltrate within the blood vessel walls were predominantly histiocytic with significant karyorrhexis, and there was presence of a few scattered CD3 1 T cells ( Fig 2) . Both CD4 1 and CD8 1 T cells were present. There were no CD20 1 and PAX5 1 B cells noted. Tissue biopsy findings for bacterial and fungal cultures were negative; acid-fast bacilli smear and cultures were also normal.
Blinatumomab was withheld, and the erythema and pain resolved completely 1 week later. After a multidisciplinary discussion with his oncologists, the decision was made to restart blinatumomab at a lower dose (5 g/m 2 /d) 23 days after his first infusion, as the drug was regarded as critical to 
DISCUSSION
From 2014 to 2015, a multicenter phase 2 study of 189 patients with ALL treated with 2 cycles of blinatumomab was conducted to evaluate the efficacy and safety profile of this drug. 3 Subsequently, blinatumomab was also studied in pediatric patients with relapsed/refractory pre-B ALL in a phase I/II clinical trial. 4 Patients received blinatumomab for 4 weeks by continuous intravenous infusion followed by a 2-week treatment-free period (for up to 5 cycles). Patients had dose escalations of 5, 15, and 30 g/m 2 /d and stepwise dosing of 5 to 15 or 15 to 30 g/m 2 /d. The adverse events reported in this study were similar to those from adult patients with relapsed/refractory B-cell precursor ALL who received body surface areaebased dosing. This is the first reported case of blinatumomabassociated medium-vessel vasculitis to our knowledge. Hypersensitivity reactions induced by monoclonal antibodies are type III hypersensitivity reactions. The mechanisms underlying drug-induced hypersensitivity reactions are still incompletely understood, but cellular and humoral immune processes are implicated. Although cutaneous vasculitis (usually a small-sized vessel vasculitis) associated with the tumor necrosis factor-a inhibitor, infliximab, in the treatment of arthritis is well known, this condition is rarely seen after monoclonal antibodyebased cancer therapy.
That the vasculitis may resolve with temporary withdrawal of the drug suggests that vasculitis may be a reversible side effect for which careful monitoring must be done. To date, the patient had tolerated the re-introduction of blinatumomab, albeit at a lower dose. It is extremely crucial to balance both the need to achieve remission in otherwise refractory/relapsed ALL patients with the need to avoid adverse events such as vasculitis that may contribute to significant morbidity or mortality. Long-term longitudinal studies are necessary to evaluate blinatumomab's safety profile, especially as it is a first-in-class biologic agent.
